Media
07
Feb

Orion Genomics launches clinical diagnostics lab, granted CAP Accreditation and CLIA certification

Post in Blog
by Super User

Orion Genomics launches clinical diagnostics lab, granted CAP accreditation

For Immediate Release
February 7, 2014

Contact:
Carolyn Hawley
Canale Communications for Orion Genomics
619-849-5375
This email address is being protected from spambots. You need JavaScript enabled to view it.

St. Louis, Missouri − February 7, 2014 − Orion Genomics, a leading developer of epigenetic − based diagnostics, announced today the receipt of certification by the College of American Pathologists, for meeting standards of excellence in the practice of laboratory medicine. On April 9, 2013, Orion Genomics also received licensure and certificate of registration from the State of Missouri as a CLIA laboratory, and launched the Orion Genomics Clinical Labs. The Centers for Medicare & Medicaid Services (CMS) ensures high − quality standards of diagnostic testing on humans through regulatory oversight through the Clinical Laboratory Improvement Amendments of 1998 (CLIA).

”CAP accreditation and CLIA certification are critical steps in the validation of our proprietary colon cancer risk test in large prospective cohorts, which can now begin under the highest performance standards in the Orion Genomics Clinical Laboratory”, said Nathan Lakey, President and Chief Executive Officer of Orion. ”These achievements also enables us to market assay design and validation services to companies with novel diagnostics in development.” The DNA molecule not only contains information based on its sequence of As, Ts, Gs and Cs but also has a second layer of information (or epigenetic layer) written on top of the DNA sequence. The second layer is based on the addition of methyl groups to the DNA molecule’s backbone, which creates a binary language that controls whether or not a gene is turned on or off, also called gene silencing. Orion’s colon cancer risk test measures the loss of imprinting (LOI) of the insulin−like Growth Factor II gene , a sporadic epigenetic defect which occurs in ~10% of the population and leads to an increased expression of a potent growth factor, a marker which may be predictive of future cancer risk. Orion exclusively licensed a portfolio of patents from the Johns Hopkin’s University covering LOI testing, and is collaborating with leading Hopkins researchers to design high performing molecular assays for LOI testing